These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 1359420)

  • 1. Progress report from the Testing Program for Stimulant and Depressant Drugs (1990).
    Patrick GA; Harris LS; Nader MA; Woolverton WL; Winger G; Woods JH
    NIDA Res Monogr; 1992; 119():604-24. PubMed ID: 1359420
    [No Abstract]   [Full Text] [Related]  

  • 2. Progress report from the testing program for stimulant and depressant drugs (1996).
    France CP; Gerak LR; Rowlett JK; Woolverton WL; Winger G; Woods JH
    NIDA Res Monogr; 1998 Mar; 178():429-39. PubMed ID: 9686406
    [No Abstract]   [Full Text] [Related]  

  • 3. Progress report from the testing program for stimulant and depressant drugs (1993).
    Patrick GA; Harris LS; Woolverton WL; Nader MA; Winger G; Woods JH
    NIDA Res Monogr; 1994; 140():248-63. PubMed ID: 8722467
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress report from the testing program for stimulant and depressant drug (1992).
    Woolverton WL; Nader MA; Winger G; Woods JH; Patrick GA; Harris LS
    NIDA Res Monogr; 1993; 132():579-94. PubMed ID: 8101976
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress report from the Testing Program for Stimulant and Depressant Drugs (1991).
    Winger G; Woods JH; Patrick GA; Powell LJ; Harris LS; Nader MA; Woolverton WL
    NIDA Res Monogr; 1992; 119():625-39. PubMed ID: 1359421
    [No Abstract]   [Full Text] [Related]  

  • 6. The guinea-pig isolated atrium as a model system for the central actions of selected CNS stimulant and depressant drugs. Part 1: 3,3-Diakylglutarimide homologues and related drugs.
    Arblaster CI; Cameron DW; Lavi Y; Laycock GM; Shulman A
    Methods Find Exp Clin Pharmacol; 1987 Aug; 9(8):503-47. PubMed ID: 2891885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing drugs for physical dependence potential and abuse liability. The Committee on Problems of Drug Dependence, Inc.
    NIDA Res Monogr; 1984; 52():1-153. PubMed ID: 6148699
    [No Abstract]   [Full Text] [Related]  

  • 8. Testing drugs for abuse liability and behavioral toxicity: progress report from the laboratories at the Johns Hopkins University School of Medicine.
    Brady JV; Griffiths RR
    NIDA Res Monogr; 1983 Apr; 43():99-124. PubMed ID: 6135997
    [No Abstract]   [Full Text] [Related]  

  • 9. Biological evaluation of compounds for their physical dependence potential and abuse liability. XI. Drug testing program of the Committee on Problems of Drug Dependence, Inc. (1987).
    Jacobson A
    NIDA Res Monogr; 1988; 81():466-84. PubMed ID: 2900468
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder.
    Calhoun PS; Sampson WS; Bosworth HB; Feldman ME; Kirby AC; Hertzberg MA; Wampler TP; Tate-Williams F; Moore SD; Beckham JC
    J Consult Clin Psychol; 2000 Oct; 68(5):923-7. PubMed ID: 11068979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological evaluation of compounds for their dependence liability. VII. Drug Testing Program of the Committee on Problems of Drug dependence, Inc. (1983).
    Jacobson AE
    NIDA Res Monogr; 1984 Mar; 49():352-60. PubMed ID: 6148694
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing abuse liability during drug development: changing standards and expectations.
    Schoedel KA; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological evaluation of compounds for their physical dependence potential and abuse liability. XVI. Drug Evaluation Committee of the College of Problems of Drug Dependence, Inc. (1992).
    Jacobson AE
    NIDA Res Monogr; 1993; 132():437-58. PubMed ID: 8101975
    [No Abstract]   [Full Text] [Related]  

  • 14. Understanding chemical dependence.
    Milhorn HT
    J Miss State Med Assoc; 1992 Apr; 33(4):123-8. PubMed ID: 1351948
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of new medications for stimulant abuse treatment.
    Woolverton WL; Kleven MS
    NIDA Res Monogr; 1992; 119():155-9. PubMed ID: 1359417
    [No Abstract]   [Full Text] [Related]  

  • 16. The guinea-pig isolated atrium as a model system for the central actions of selected CNS stimulant and depressant drugs. Part 2. Mechanisms involved in the actions and interactions of the convulsant bemegride and its hypnotic homologue 3-methyl-3-n-butylglutarimide.
    Arblaster CI; Cameron DW; Lavi Y; Laycock GM; Shulman A
    Methods Find Exp Clin Pharmacol; 1988 Mar; 10(3):177-211. PubMed ID: 2455201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common substrates of dysphoria in stimulant drug abuse and primary depression: therapeutic targets.
    Baicy K; Bearden CE; Monterosso J; Brody AL; Isaacson AJ; London ED
    Int Rev Neurobiol; 2005; 65():117-45. PubMed ID: 16140055
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of acute drug abuse reactions.
    Med Lett Drugs Ther; 1987 Sep; 29(748):83-6. PubMed ID: 2888009
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of central nervous system depressant, stimulant and hallucinogenic drugs on injury severity in patients admitted for trauma.
    Cordovilla-Guardia S; Lardelli-Claret P; Vilar-López R; López-Espuela F; Guerrero-López F; Fernández-Mondéjar E
    Gac Sanit; 2019; 33(1):4-9. PubMed ID: 28784303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute drug abuse reactions.
    Med Lett Drugs Ther; 1985 Sep; 27(696):77-80. PubMed ID: 2863741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.